Brokers expect Mediwound Ltd (NASDAQ: MDWD) to make $ 1.11 million in revenue for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Mediwound's earnings, with estimates ranging from $ 930,000.00 to $ 1.29 million. Mediwound achieved sales of $ 740,000.00 in the same quarter last year, suggesting a positive annual growth of 50%. The company is expected to announce the results of its quarterly results on Thursday, November 15th.
On average, analysts expect Mediwound to report annual sales of $ 3.47 million for the current year, with estimates ranging from $ 2.79 million to $ 3.80 million. For the next financial year, analysts predict that the company will report sales of $ 11.61 million per share, with estimates ranging from $ 5.81 million to $ 14.80 million. The sales calculations of Zacks Investment Research are an average average based on a study by research analysts following Mediwound.
Mediwound (NASDAQ: MDWD) last released its quarterly results on Tuesday 7 August. The biopharmaceutical company reported ($ 0.15) EPS for the quarter, on top of the consensus estimate of ($ 0.20) with $ 0.05. Mediwound had a negative return on equity of 210.90% and a negative net margin of 783.30%. The company's revenue was $ 1.03 million compared to analyst estimates of $ 0.96 million.
Several analysts have recently released reports about the company. Wells Fargo & Co set a price target of $ 11.00 on Mediwound and gave the company a "buy" score in a study letter on Wednesday, August 8th. Oppenheimer set a target price of $ 14.00 on Mediwound shares and gave the company a "buy" score in a research report on Tuesday, August 7th. Zacks Investment Research lowered the shares of Mediwound from a & # 39; hold & # 39; credit to a & # 39; sell & # 39; rating in a research report on Wednesday 11 July. Finally, ValuEngine upgraded Mediwound shares from a "sell" classification to a "hold" rating in a research report on Friday, June 1. One analyst has rated the shares with a sell rating, one has given a hold rating and five have given a buy rating to the company. Mediwound currently has a consensus score of "buy" and an average price target of $ 9.79.
NASDAQ MDWD shares traded $ 0.12 during Friday afternoon trading and reached $ 6.28. The company had a trading volume of 8,793 shares, compared with the average volume of 29,779. The share has a market capitalization of $ 171.75 million, a P / E ratio of -10.12 and a beta of -0.16. Mediwound has a 1-year low of $ 3.56 and a 1-year high of $ 7.35.
Several hedge funds have recently bought and sold MDWD shares. Wells Fargo & Company MN increased the share in Mediwound by 84.6% in the fourth quarter. Wells Fargo & Company MN now owns 101,189 shares in the share capital of the biopharmaceutical company worth $ 450,000 after the purchase of an additional 46,666 shares during the period. Renaissance Technologies LLC increased its position in Mediwound in the 4th quarter by 18.2%. Renaissance Technologies LLC now owns 100,600 shares in the share capital of the biopharmaceutical company with a value of $ 448,000, after having acquired another 15,500 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. has reduced its position in Mediwound by 1.0% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now holds 2,098,277 shares in the share capital of the biopharmaceutical company with a value of $ 14,478,000 after acquiring another 21,559 shares in the last quarter. Finally, in the second quarter, Nexthera Capital LP bought a new shareholding in Mediwound worth approximately $ 308,000. Institutional investors hold 32.94% of the company's shares.
About Mediwound
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, producing and commercializing new therapeutic products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep, partial and complete thermal burns in the European Union, Israel and Argentina.
Featured article: marijuana stocks that take into account considerations
Receive a free copy of the Zacks research report on Mediwound (MDWD)
Visit Zacks.com for more information about research offers from Zacks Investment Research
Receive news and ratings for Mediwound Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst ratings for Mediwound and related companies with the FREE daily email newsletter from MarketBeat.com.
Source link